IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

SIENA, SALVATORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 31.528
AS - Asia 26.978
NA - Nord America 22.758
SA - Sud America 2.407
AF - Africa 577
OC - Oceania 457
Continente sconosciuto - Info sul continente non disponibili 37
Totale 84.742
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.426
DE - Germania 11.188
CN - Cina 11.002
GB - Regno Unito 6.743
SG - Singapore 5.313
IT - Italia 4.305
HK - Hong Kong 2.102
RU - Federazione Russa 1.984
BR - Brasile 1.774
VN - Vietnam 1.510
JP - Giappone 1.362
FR - Francia 1.346
IN - India 1.270
SE - Svezia 1.026
CA - Canada 998
KR - Corea 833
IE - Irlanda 811
BD - Bangladesh 808
FI - Finlandia 751
NL - Olanda 675
ES - Italia 673
TR - Turchia 632
ID - Indonesia 446
AU - Australia 391
TW - Taiwan 363
CH - Svizzera 245
AT - Austria 217
PL - Polonia 215
IR - Iran 212
MX - Messico 201
AR - Argentina 193
DK - Danimarca 188
RO - Romania 166
BE - Belgio 165
GR - Grecia 141
UA - Ucraina 128
TH - Thailandia 124
IQ - Iraq 118
ZA - Sudafrica 114
PT - Portogallo 112
CO - Colombia 111
PK - Pakistan 110
MY - Malesia 107
IL - Israele 102
PH - Filippine 102
EU - Europa 101
EC - Ecuador 100
NO - Norvegia 99
CL - Cile 91
SA - Arabia Saudita 82
CI - Costa d'Avorio 81
EG - Egitto 77
CZ - Repubblica Ceca 71
NZ - Nuova Zelanda 65
DZ - Algeria 63
MA - Marocco 61
JO - Giordania 60
HU - Ungheria 52
UZ - Uzbekistan 51
TN - Tunisia 46
PE - Perù 43
LB - Libano 39
VE - Venezuela 37
AE - Emirati Arabi Uniti 35
KE - Kenya 32
SK - Slovacchia (Repubblica Slovacca) 29
CR - Costa Rica 27
LT - Lituania 26
RS - Serbia 26
BG - Bulgaria 24
HR - Croazia 21
JM - Giamaica 20
PY - Paraguay 20
NP - Nepal 19
UY - Uruguay 19
AM - Armenia 18
KZ - Kazakistan 18
CY - Cipro 17
SC - Seychelles 17
ET - Etiopia 16
NG - Nigeria 16
BO - Bolivia 15
OM - Oman 15
AZ - Azerbaigian 14
LU - Lussemburgo 14
MO - Macao, regione amministrativa speciale della Cina 14
PA - Panama 14
PS - Palestinian Territory 14
LK - Sri Lanka 13
SI - Slovenia 13
EE - Estonia 12
AL - Albania 11
TT - Trinidad e Tobago 11
GE - Georgia 10
GT - Guatemala 10
BY - Bielorussia 9
HN - Honduras 9
MK - Macedonia 9
BB - Barbados 8
QA - Qatar 8
Totale 84.645
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 9.535
Southend 5.065
Singapore 2.822
Hangzhou 1.756
Ashburn 1.741
Hong Kong 1.609
Beijing 1.519
Milan 1.316
San Jose 1.136
Chandler 1.040
Seattle 989
Fairfield 857
Council Bluffs 837
Wilmington 783
Dublin 773
Princeton 743
Shanghai 733
Dallas 639
Houston 619
Guangzhou 595
Los Angeles 583
Redwood City 558
New York 525
Nanjing 505
Helsinki 449
Woodbridge 440
Tokyo 435
Ho Chi Minh City 419
Cambridge 396
Lauterbourg 378
Santa Clara 365
Hefei 347
Dearborn 333
Hanoi 332
Bengaluru 324
Jakarta 304
Buffalo 291
Ann Arbor 285
Moscow 281
Des Moines 258
Rome 254
Ottawa 244
Toronto 221
London 199
Taipei 190
Tianjin 188
Munich 186
Columbus 183
Jinan 174
Seoul 174
São Paulo 174
Redmond 170
Shenyang 169
Phoenix 160
Chicago 159
Istanbul 153
Berlin 148
Boardman 147
The Dalles 147
Changsha 146
Chengdu 135
Turin 135
Madrid 134
Dong Ket 131
Wuhan 131
Shenzhen 130
Central District 129
Nuremberg 128
Boston 124
Barcelona 117
San Diego 114
Vienna 110
Cangzhou 105
Amsterdam 102
Duncan 98
Zhengzhou 98
Paris 97
Mountain View 94
Nanchang 94
Hebei 92
Atlanta 86
Central 86
Abidjan 81
Montreal 81
Bologna 77
Melbourne 77
Mumbai 77
Chennai 76
Manchester 76
Sakarya 76
Hyderabad 75
Fuzhou 73
Regensburg 72
Naples 71
Hanover 70
Sydney 69
Washington 69
Torino 68
Falls Church 66
Haiphong 66
Totale 50.291
Salva come PNG Salva come JPEG
Nome #
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer 7.438
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer 3.518
Liquid biopsy for rectal cancer: a systematic review 1.712
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial 1.330
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy 1.254
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets 1.103
Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes 914
Entrectinib for the treatment of metastatic NSCLC: safety and efficacy 854
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer 810
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin 807
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond 700
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study 699
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 687
Early-onset colorectal cancer in young individuals 672
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 629
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies 569
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials (ALKA-372-001 and STARTRK-1) 540
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer 539
Increased incidence of colon cancer among individuals younger than 50 years : a 17 years analysis from the cancer registry of the municipality of Milan, Italy 481
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition 438
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer 415
KRAS mutations testing in colorectal carcinoma patients in Italy: From guidelines to external quality assessment 411
Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy 401
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression 400
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors 395
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 392
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer 390
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion 388
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 384
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer 342
Exploring the links between cancer and placenta development 340
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib 334
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 316
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility : a Single-Institution Experience 315
The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer 313
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer 300
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer 299
Strategies to tackle RAS-mutated metastatic colorectal cancer 291
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer 289
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 289
Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET) 289
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 287
Concurrent small cell transformation and emergence of trans-C797S and T790M mutations under sequential treatment with EGFR inhibitors in lung adenocarcinoma 283
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient 281
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer : a retrospective consortium analysis 279
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer 279
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 275
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) 273
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ 272
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial 270
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment 266
Detection of circulating tumor DNA in early- and late-stage human malignancies 265
Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab 264
Platelet cryopreservation using second-messenger effector and low-dose (2%) dimethyl sulfoxide. In vitro evaluation of post-thawing platelet activity with the platelet function analyzer 262
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery : a multicenter phase II study 262
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment 262
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 260
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case 259
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies 257
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 254
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA 253
The quest for improving treatment of cancer of unknown primary (CUP) through molecularly-driven treatments: a systematic review 251
Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation 251
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas 250
Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review 248
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer : a retrospective, exploratory analysis of the CORRECT trial 246
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma : results from the NEMESI study 245
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials 240
Adaptive mutability of colorectal cancers in response to targeted therapies 238
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 238
Circulating tumor DNA to drive treatment in metastatic colorectal cancer 236
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. 235
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : Results from two randomized first-line panitumumab studies 235
H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22) 234
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer 232
Ex vivo expansion of hematopoietic cells and their clinical use 230
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial 229
Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma 227
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer 227
Central Nervous System as Possible Site of Relapse in ERBB2-PositiveMetastatic Colorectal Cancer:Long-term Results of TreatmentWith Trastuzumab and Lapatinib 227
Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study 225
Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features 223
Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 223
The genomic landscape of response to EGFR blockade in colorectal cancer 223
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer 223
Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature 223
TRKA expression and NTRK1 gene copy number across solid tumours 222
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC 220
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status 220
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types 219
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer 218
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer 217
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review 217
Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast 216
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients 215
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer 214
Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases 214
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review 213
Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies 212
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer 212
Totale 47.238
Salva come PNG Salva come JPEG
Categoria #
all - tutte 194.363
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 194.363
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.163 0 0 0 0 0 0 0 0 0 0 590 573
2021/20227.047 579 542 513 539 703 422 525 489 665 621 441 1.008
2022/20236.519 793 555 485 626 563 1.170 327 421 607 208 426 338
2023/202412.661 396 490 467 506 1.084 878 1.693 1.542 745 1.421 1.690 1.749
2024/202513.326 1.559 1.698 1.286 1.267 700 655 599 1.159 681 870 1.018 1.834
2025/202621.594 1.917 1.396 2.275 1.709 2.040 1.680 2.518 1.370 2.590 1.578 2.521 0
Totale 88.025